Phase I Study of Denintuzumab Mafodotin in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma


Phase I Study of Denintuzumab Mafodotin in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Michelle A Fanale, MD (2/18/16)
Moskowitz CH et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in relapsed/refractory B-lineage non-Hodgkin lymphoma. Proc ASH 2015;Abstract 182.

Dr Fanale is Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas.